Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.
<h4>Background</h4>Hypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT). Mavacamten, a first-in-class cardiac myosin inhibitor, is increasingly being...
Main Authors: | Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0301704&type=printable |
Similar Items
-
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
by: Smita Scholtz, et al.
Published: (2023-10-01) -
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
by: Dong T, et al.
Published: (2023-04-01) -
Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
by: Susan Mathai, et al.
Published: (2022-11-01) -
Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten
by: Jorik H. Amesz, et al.
Published: (2024-01-01) -
Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
by: Areeba Memon, et al.
Published: (2023-12-01)